Clinical Trial Update: Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study) [Phase 2]

View source ↗

Summary

Phase 2 trial update on apremilast (CC-10004) for moderate-to-severe plaque-type psoriasis with efficacy and safety findings completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque-type Psoriasis
• Psoriasis

Drugs mentioned

• Apremilast (apremilast)

Snippet

Sponsor: Amgen | Conditions: Psoriasis, Plaque-type Psoriasis | Phase 2 | Status: COMPLETED | Results posted: 2014-11-13